Galderma vs Merz Group

Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older

Galderma's latest press release announces new three-year data for Nemluvio® in atopic dermatitis, presented at Fall Clinical 2026.

EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis

Galderma announced new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) provides sustained improvements in moderate-to-severe atopic dermatitis for up to 152 weeks. At Week 152, up to 91% of patients achieved EASI-75, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life. The findings were presented at the EADV 2026 Congress in Vienna, Austria, which runs September 30 to October 3, 2026. Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis in more than 40 countries.

• Galderma published the press release on September 30, 2026, announcing new three-year ARCADIA long-term extension data for Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis.
• At Week 152, up to 91% of patients achieved EASI-75, up to 75% achieved EASI-90, up to 67% achieved IGA 0/1, up to 88% achieved clinically meaningful itch relief, and up to 92% achieved clinically meaningful quality-of-life improvement.
• The findings were presented at the EADV 2026 Congress in Vienna, Austria, with the oral presentation scheduled for Thursday, October 1, 2026.

Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies

Galderma has been added to the Swiss Market Index (SMI), marking its inclusion among Switzerland's leading blue-chip companies. This is a major corporate milestone for the company.